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The adaptive immune system depends on the sequence of antigen presentation, activa-
tion, and then inhibition to mount a proportionate response to a threat. Tumors evade the 
immune response partly by suppressing T-cell activity using immune checkpoints. The 
use of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 
(PD-1), and programmed cell death ligand 1 (PD-L1) antibodies counteract this suppres-
sion, thereby enhancing the antitumor activity of the immune system. This approach has 
proven efficacy in melanoma, renal cancer, and lung cancer. There is growing evidence 
that the central nervous system is accessible to the immune system in the diseased state. 
Moreover, glioblastomas (GBMs) attract CTLA-4-expressing T-cells and express PD-L1, 
which inhibit activation and continuation of a cytotoxic T-cell response, respectively. This 
may contribute to the evasion of the host immune response by GBM. Trials are in prog-
ress to determine if checkpoint inhibitors will be of benefit in GBM. Radiotherapy could 
also be helpful in promoting inflammation, enhancing the immunogenicity of tumors, 
disrupting the blood–brain barrier and creating greater antigen release. The combination 
of radiotherapy and checkpoint inhibitors has been promising in preclinical trials but 
is yet to show efficacy in humans. In this review, we summarize the mechanism and 
current evidence for checkpoint inhibitors in gliomas and other solid tumors, examine the 
rationale of combining radiotherapy with checkpoint inhibitors, and discuss the potential 
benefits and pitfalls of this approach.
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inTRODUCTiOn
The recent exciting developments in immune checkpoint inhibitors have opened novel therapeutic 
avenues in previously intractable cancers. This has resulted in striking clinical benefits particularly 
in melanoma and renal-cell cancer (1–3). There are many checkpoint molecules that regulate the 
immune system to prevent over or under activation. Checkpoint inhibitors such as nivolumab 
or pembrolizumab (programmed cell death 1 or PD-1 inhibitors) and ipilimumab (a cytotoxic 
T-lymphocyte-associated protein 4 or CTLA-4 inhibitor) enhance the immune response to a tumor. 
Glioblastomas (GBMs) have multiple immunosuppressive effects involving programmed cell death 
FiGURe 1 | An overview of the inhibitory and co-stimulatory interactions between antigen-presenting cells and T-cells [adapted with permission from Macmillan 
Publishers Ltd., copyright 2012 (3)].
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ligand 1 (PD-L1) (4) and CTLA-4 checkpoints (5). The use of 
checkpoint inhibitors to upregulate the immune response in 
GBMs is under investigation in several clinical trials.
This paper aims to review the immune system in the central 
nervous system (CNS), how GBM evades it, and the evidence for 
checkpoint inhibition in non-CNS cancers. We will then discuss 
the current trials of checkpoint inhibitors in GBM and the ration-
ale for combining them with radiotherapy.
THe iMMUne SYSTeM in THe CnS
The immune system can be divided into two types of response, 
the innate (non-specific) and the adaptive (targeted) response. The 
latter relies on antigen presentation to T-cells by antigen- 
presenting cells (APCs) such as B-cells, macrophages, and 
dendritic cells (DC), while the former utilizes physical bounda-
ries and non-specific inflammation. The CNS is protected by 
the blood–brain barrier (BBB), which consists of specialized 
endothelial cells joined together by tight junctions, as well as the 
glia limitans, a combination of astrocyte foot processes and base-
ment membranes (6). The BBB serves to maintain CNS homeo-
stasis and restrict entry of pathogens. The adaptive response in 
the CNS may be triggered in several ways: by the flow of soluble 
antigens to the draining deep cervical lymph nodes, where it is 
taken up by peripheral APCs; by DC near the meninges; or by 
microglia (the APC intrinsic to the CNS) (7). This differs from 
the peripheral immune system, where APCs migrate from the 
source of inflammation carrying the antigen to the lymph 
nodes or spleen, at which point antigen presentation occurs 
to T- and B-cells. Moreover, the neurons and astrocytes in the 
non-diseased state have an immunosuppressive action mediated 
by programmed cell death 1 (PD-1) and co-stimulatory molecule 
B7 homologs that restrict antigen presentation and downregulate 
T-cell function (8). However, in the diseased state, the BBB is 
disrupted, which allows immune cells greater access to the CNS.
The activity of the immune system is tightly regulated by stim-
ulatory and inhibitory interactions between the APC and T-cells. 
To activate T-cells, the APC must present the foreign antigen 
to the T-cell receptor. This interaction in isolation causes T-cell 
anergy. Further stimulatory signals from the APC are required to 
activate the T-cell, such as activation of CD28 by CD80/86 (see 
Figure 1). Conversely, if the APC expresses ligands that activate 
CTLA-4, this inhibits T-cell activation. The perpetuation of any 
T-cell response depends in part on the PD-1/PD-L1 interaction— 
if this occurs, then effector T-cells are unable to mount a persistent 
immune response (9). These competing signals act as checkpoints 
to prevent immune hyperstimulation or autoimmunity while 
generating a proportionate response to pathogens.
Cancer cells produce tumor antigen that can generate an 
immune response, as shown by the presence of tumor-infiltrating 
lymphocytes (TILs) into many solid tumors, including GBM 
(10, 11). However, T-cell activation is limited by both the recruit-
ment of T-regs (expressing CTLA-4) into the tumor stroma and 
the suppression of any activated T-cells by GBM expression of 
PD-L1. In addition, tumor-infiltrating macrophages (which can 
constitute as much as 33% of the cell mass of a GBM) appear 
to have an immunosuppressive effect governed by the signal 
transducer and activator of transcription 3 (STAT3) pathway. 
Glioma cells express high STAT activity (12); therefore, tumor 
immunosuppression likely arises from effects on both T-cells and 
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macrophages. The role of the CTLA-4 and PD-1 checkpoints has 
been investigated in GBM, as detailed below.
Cytotoxic T-Lymphocyte-Associated 
Protein 4
Cytotoxic T-lymphocyte-associated protein 4 acts as a negative 
signaling antigen on activated T-cells, memory T-cells, and T-reg 
cells, competing with CD28 to interact with CD80 and CD86 on 
other T-cells (see Figure 1) (13). T-regs are CD4+ T-cells express-
ing the FoxP3 gene and appear to be the main coordinator of 
immunosuppression using CTLA-4 signaling (14, 15). Chambers 
et al. hypothesized that CTLA-4 acts via a threshold mechanism, 
lowering the immune response by altering the activation thresh-
old for T-cell activation and decreasing clonal expansion (16).
Tivol et al. showed that mice deficient in CTLA-4 cannot nega-
tively regulate T-cell proliferation leading to lymphoproliferative 
disorders and death (17). Fecci et al. have reported a correlation 
between an increased T-reg fraction and defects in CD4 cell 
proliferation in GBM. This study analyzed peripheral blood and 
tumor samples from GBM patients (n = 20) and healthy volunteers 
(n = 10). In GBM patients, the overall CD4+ T-cell numbers were 
decreased in both peripheral blood and the tumors compared to 
controls, but the fraction of T-regs within the CD4+ population 
was 2.63 times greater in the GBM group (18). Jacobs et al. dem-
onstrated that GBM-infiltrating T-regs have high expression of 
CCR4, which is a receptor for the glioma-secreted chemokines 
CCL2 and CCL22, which may explain the increase in T-regs in 
glial tumors (19, 20). The constitutive expression of CTLA-4 on 
T-regs and their increase in GBM patients raises the possibility 
that anti-CTLA-4 monoclonal antibodies (e.g., ipilimumab) can 
be used for therapeutic benefit. However, a study of ipilimumab 
in melanoma and prostate cancer found that there were more 
FoxP3-positive (therefore immunosuppressive) T-regs in cancer 
patients treated with ipilimumab than in untreated patients with-
out a cancer diagnosis suggesting that the mechanism of action of 
CTLA-4 is yet to be fully explained (21).
Programmed Cell Death Ligand 1
Programmed cell death ligand 1 (see Figure 1) is the ligand of PD-1 
and may be expressed on normal T-cells, B-cells, DC, and natural 
killer cells, as well as non-lymphoid tissue (14). An immunohisto-
chemical study in GBM specimens found PD-L1 expression was 
prevalent with 60% of samples having at least 1% or more positive 
cells. In addition to staining on GBM cells, PD-L1 expression was 
found on lymphocyte-like cells, representing up to 28.6% of the 
positive cells counted. Moreover, GBM patients from the same 
study with high PD-1 and PD-L1 expression had worse survival 
outcomes, with an overall survival of 6.21  months shorter than 
those with low expression (22). In addition, Wintterle et al. found 
PD-L1 protein expression in both GBM (n = 9) and WHO Grade II 
mixed glioma (n = 1) specimens. The authors also found that PD-L1 
is expressed constitutively at low levels in many malignant glioma 
cell lines (4). Moreover, Parsa et al. suggest that PD-L1 expression 
may be upregulated in certain glioma cell lines and a small number 
of GBM tissue specimens with a PTEN gene mutation or deletion, 
which is associated with a worse prognosis (23, 24).
iMMUne CHeCKPOinT inHiBiTORS in 
nOn-CnS CAnCeRS
CTLA-4 inhibitors
Ipilimumab, an anti-CTLA-4 monoclonal antibody, has shown 
efficacy in metastatic melanoma. A phase 3 study combining 
ipilimumab and the alkylating agent dacarbazine was compared 
to treatment with placebo and dacarbazine. Median overall 
survival increased from 9.1  months in the dacarbazine group 
to 11.2  months with combination therapy (25). However, in 
small cell lung cancer, the addition of ipilimumab to platinum 
and etoposide was of no additional benefit in terms of overall 
survival (26). This highlights how immunotherapy has variable 
effects across tumor types.
Anti PD-1 Monoclonal Antibodies
Nivolumab, a PD-1 inhibitor, has also been extensively used 
as an immunotherapeutic agent in several cancers with good 
efficacy. In untreated melanoma patients without a BRAF 
V600E mutation, nivolumab treatment alone had a 72.9% 
overall survival at 1 year compared to 42.2% with dacarbazine 
treatment (27). Treatment with nivolumab has also been 
investigated in recurrent lung cancer. A 3-month survival ben-
efit was observed in both squamous and non-squamous lung 
cancer when nivolumab was compared to docetaxel (28, 29). 
In advanced renal-cell carcinoma patients who had previously 
undergone antiangiogenic therapy, nivolumab was compared 
to everolimus, an mTOR inhibitor (2). This trial showed a 
median overall survival of 25.0 months in the nivolumab group 
(n =  406) compared to 19.6  months in the everolimus group 
(n = 397).
These trials have all looked at the possibility of using PD-1, 
or its ligand PD-L1, as a predictive marker of response. In mela-
noma, there was no correlation between response and PD-1 
expression. This was also the case for squamous lung cancer 
and renal-cell cancer. However, in non-squamous lung cancer 
increased PD-L1 expression was indicative of a better outcome, 
indicating that in some cancer types determining PD-1 or 
PD-L1 expression may be beneficial to determining optimal 
treatment. The combination of nivolumab and ipilimumab 
compared against both agents alone has been assessed in a 
phase 3 trial in metastatic melanoma (30). Combination treat-
ment gave a PFS of 11.5 months, nivolumab alone 6.9 months, 
and ipilimumab alone 2.9 months. The combination resulted in 
increased toxicity with 55% of patients experiencing grade 3 or 
4 side effects. It does however highlight the additional efficacy 
of combining different checkpoint inhibitors in the treatment 
of cancer.
Newer PD-1 inhibitors have also become available. Pembroli-
zumab is a high-affinity humanized PD-1 monoclonal antibody, 
which in a phase 3 study was compared with ipilimumab treat-
ment in melanoma patients with BRAF V600E mutations (31). 
Pembrolizumab had an overall response rate of 33.7% compared 
to 11.9% in the ipilimumab group and an increased median PFS of 
5.5 months (n = 279) compared to 2.8 months in the ipilimumab 
group (n = 278).
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Anti-PD-L1 Monoclonal Antibodies
PD-1 binds to the checkpoint molecule PD-L1. In addition to 
inhibiting PD-1, an alternative strategy has been to develop 
antibodies against PD-L1. One such monoclonal antibody is 
atezolizumab, which has been investigated in metastatic renal-
cell carcinoma. A phase 1a trial showed that the drug was well 
tolerated in a group of 70 patients (32). In non-small cell lung 
cancer, durvalumab, a human IgG1 monoclonal antibody against 
PD-L1, has been trialed in a phase 1b study in combination with 
tremelimumab, a monoclonal antibody targeting CTLA-4 (33). 
Clinical activity was noted regardless of PD-L1 status, and the 
combination of drugs was tolerated manageably. Phase 3 trials are 
currently ongoing in these new drugs and hopefully will provide 
additional treatment options.
Current immunotherapy Trials in GBM
The rationale for the use of checkpoint inhibitors in GBM is 
to harness the specificity of the adaptive immune response by 
blocking the tumor-induced inhibition of the T-cell response 
thereby promoting immune-mediated cytotoxicity. There is one 
large unblinded randomized phase 3 trial looking at nivolumab 
in newly diagnosed MGMT unmethylated GBM, CHECKMATE 
498, which has just closed to recruitment. This compares the 
standard Stupp regimen of temozolomide with radiotherapy, with 
nivolumab and radiotherapy, with overall survival as the primary 
endpoint. Temozolomide has been omitted from the experimen-
tal arm due to the small benefit in unmethylated patients and 
potential negative effect of chemotherapy on the immune system. 
There is also a double-blinded sister study, CHECKMATE 548, 
in methylated MGMT patients, where both arms are treated with 
the Stupp regimen, and nivolumab is compared to placebo. This 
trial is currently recruiting and is looking at overall survival as 
the primary endpoint. There are three current smaller trials using 
another PD-1 inhibitor, pembrolizumab. The first is a phase 2 
study in recurrent GBM (NCT02337491) combining pembroli-
zumab with VEGF inhibitor bevacizumab versus pembrolizumab 
alone (34). Preliminary results show safety and tolerability of 
pembrolizumab in combination with bevacizumab, with a median 
overall survival of 6.8 months in a cohort of six patients. Another 
phase 2 trial, also in recurrent GBM (NCT02337686), is giving 
all study participants the drug before surgical resection and then 
continual doses after surgery until disease progression in order 
to obtain data on 6-month PFS and effector T-cell to T-reg ratio 
(35). In the third, pembrolizumab is also being trialed in newly 
diagnosed GBM, in a phase 1/2 study (NCT02530502) looking 
at pembrolizumab in combination with standard temozolomide 
and radiation treatment to ascertain dose-limiting toxicity and 
6-month PFS (36).
Programmed cell death ligand 1 inhibitors are also being 
currently investigated in early clinical trials. There are two 
current open phase 1 and phase 2 studies (NCT01375842 and 
NCT02458638) looking at atezolizumab in solid cancers includ-
ing GBM, the results of which are awaited (37, 38). An ongoing 
phase 2 study (NCT02336165) in GBM is looking at durvalumab 
in GBM both as monotherapy and in combination with bevaci-
zumab, with primary endpoints of clinical efficacy, overall sur-
vival, and 6-month progression-free survival (39).
Combination immunotherapy in GBM
A review by Intlekofer and Thompson has put forward a ration-
ale for combined blockade of CTLA-4 and PD-1 by suggesting 
that this could increase the immune response to the tumor by 
lowering the threshold of T-cell activation and enabling clonal 
expansion while simultaneously increasing effector T-cell func-
tion (14). Indoleamine 2,3-dioxygenase (IDO) is one of several 
immune checkpoints involved in tumor immune escape. The 
IDO enzyme, activated in DC and macrophages, helps create an 
environment that favors suppression and tolerance. Wainwright 
et al. showed therapeutic inhibition of IDO, CTLA-4, and PD-L1 
in a mouse model of well-established glioma maximally decreases 
tumor-infiltrating T-regs, coincident with a significant increase 
in T-cell-mediated long-term survival (40). In fact, 100% of mice 
bearing intracranial tumors were long-term survivors following 
triple combination therapy.
Bristol-Myers Squibb is looking at the efficacy and safety of 
nivolumab versus bevacizumab and nivolumab with or without 
ipilimumab in GBM in a recruiting phase 3 study (CHECKMATE 
143). This trial assesses the combination of two modes of immu-
notherapy while also looking to compare the efficacy of immu-
notherapy with antiangiogenic therapy. The primary endpoints 
are safety and tolerability in cohorts receiving either nivolumab 
alone or nivolumab and ipilimumab, and overall survival in the 
arm comparing nivolumab treatment to bevacizumab treatment. 
Secondary endpoints are overall survival at 12  months, pro-
gression-free survival, and objective response rate. Preliminary 
results as expected show that treatment with nivolumab alone 
is better tolerated than combination treatment with nivolumab 
and ipilimumab (41). A phase 2 study (NCT02794883), looking 
at combination therapy with durvalumab and tremelimumab in 
recurrent malignant glioma, will provide an interesting parallel 
to CHECKMATE 143 by targeting PD-L1 and CTLA-4 instead 
of PD-1 and CTLA-4 (42).
The Potential for immunotherapy and 
Radiotherapy in Glioma
The presentation of tumor antigen by APCs to T-cells provides 
the initial signal for the immune system to target malignant cells, 
and CTLA-4 or PD-1/PD-L1 antibodies serve to disinhibit the 
response. A complementary strategy would be to enhance the 
immunogenicity of the tumor. Ionizing radiation achieves this 
in multiple ways: release of pro-inflammatory cytokines (such 
as interferon-γ), increased production and variety of tumor-
associated antigens, and expression of molecules on tumor cells 
that make them susceptible to T-cell-mediated killing (calreti-
culin, MHC class 1, CD95, and NKGD2) (15, 43). Fractionated 
radiotherapy can induce PD-L1 expression in tumor cells and 
enhance immune escape, which could be modified by an anti-
PD-L1 antibody (44). In addition, radiation increases the ratio of 
T-effector cells compared to T-reg cells and promotes infiltration 
of T-cells into the tumor microenvironment, not only by inducing 
inflammation but also by direct vascular damage that allows DC 
to access tumor antigen and to mature into APCs (45, 46). Radio-
immunotherapy potentially could tip the balance in the tumor 
environment from immunosuppression to immune activation.
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The abscopal effect, the uncommon phenomenon seen 
clinically where tumor shrinkage occurs at a location distant 
from the area irradiated, is likely to be a result of the above 
processes (47). Mouse models suggest that this effect is 
mediated by T-cells and DC (48). Adding a CTLA-4 inhibitor 
enhanced the abscopal effect in mice inoculated with breast 
cancer cells in two sites, where only one site was irradiated 
(49). In glioma cells injected into mouse striatum, the com-
bination of CTLA-4 blockade, 4-1BB activation (4-1BB, when 
activated, stimulates CD8+ T-cell proliferation), and radio-
therapy significantly improved overall survival compared to a 
single modality alone (50). Subsequent biopsies confirmed a 
significantly higher number of CD4+ and CD8+ T-cells in the 
tumors that received all three treatments. Similarly, in mice 
implanted with glioma cells, radiotherapy with an anti-PD-1 
antibody resulted in a long-term cure rate of 15–40%, while 
neither treatment alone produced long-term responses (45). 
As GBM cells can migrate throughout the CNS and therefore 
outside of a conventional radical radiotherapy field, using 
immunotherapy to potentiate the abscopal effect is an attrac-
tive possibility (51).
Human trials testing this concept are ongoing. A phase 3 trial, 
in the setting of metastatic prostate cancer, compared the use 
of ipilimumab alone against ipilimumab and radiotherapy and 
failed to demonstrate an overall survival benefit (52). Phase 1 
and 2 studies in multiple different tumor sites continue, mainly 
with CTLA-4 blockade (or other novel immune targets such as 
OX40) with radiotherapy (53). Combination therapy in the CNS 
has several theoretical risks such as immune hyperstimulation in 
a tissue that can ill tolerate excess inflammation and damage. The 
usual milieu of the CNS is immunosuppressive, and to stimulate 
the immune system to overcome this may increase the risk of 
autoimmune damage elsewhere in the body. In addition, while 
checkpoint inhibitors may increase the activity of TILs, it is 
unclear how much this will affect tumor-associated macrophages 
and microglia. It is unclear what the ideal dose and fractiona-
tion of radiotherapy is required to generate an immune effect 
in vivo. The overall effect in humans of multimodality immune 
manipulation is difficult to predict, and we await the results of 
the ongoing research.
COnCLUSiOn
Immunotherapy is now an established modality of treatment for 
melanoma and lung cancer and is under investigation in CNS 
tumors. GBM  cells express inhibitory signals that prevent the 
immune system from mounting a significant antitumor response, 
and ongoing clinical trials will assess whether PD-1 and/or 
CTLA-4 inhibitors can overcome this. Radiotherapy potentially 
could increase numbers of active TILs in the CNS (by enhancing 
antigen presentation, increasing tumor immunogenicity, and 
making the BBB more porous) while immunotherapy could 
block the inhibition of TILs by GBM cells and T-regs, creating a 
larger response in the tumor (Figure 2). This approach may not 
be effective because of access of drugs or T-cells into the CNS, 
the prevailing immunosuppressive environment of the brain, 
or anatomical differences of the immune system in the CNS. 
Moreover, the combination of treatment could provide immune 
hyperstimulation and unacceptable toxicity. However, given the 
unacceptable prognosis of GBM, this novel approach is worthy 
of further research.
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FiGURe 2 | (A) Inhibition of the tumor-infiltrating lymphocytes (TILs) due to PD-1/programmed cell death ligand 1(PD-L1) interactions and cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) interactions. (B) Checkpoint inhibition of CTLA-4 and PD-1 reduce TIL suppression and increase TIL activity. (C) Radiotherapy 
releases more tumor antigens causing greater TIL activation. In the context of checkpoint inhibition, this may cause more immune-mediated cell death.
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